echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: BRCAness and tumor inflammatory gene expression characteristics in early hormone-positive breast cancer patients.

    Clin Cancer Res: BRCAness and tumor inflammatory gene expression characteristics in early hormone-positive breast cancer patients.

    • Last Update: 2020-10-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Early breast cancer patients who are positive for estrogen and/or progesterone are able to benefit from hormone therapy, however, the global high burden of death due to high prevalence and long-term risk of recurrence requires biomarkers to guide other treatments.
    In a forward-looking, observational study, panel, which uses 360 genes for breast cancer, tested the expression of 612 tumor genes in patients treated with tymoxifen or aromatase inhibitors in early post menophageal breast cancer to analyze 23 breast cancer pathfages.
    candidate markers associated with disease subtypes and event-free survival (EFS) were obtained through clustering analysis, Cox models, and conditional inference trees, and 613 breast marker patients were independently tested.
    the tumor-soaked lymphocytes (TIL) on tissue slices and the mutation burden of 36 tumors was assessed by sequencing the whole exon group.
    the PAM50-derived classification method distinguishes low-risk (Luminal A) from high-risk sub-type (Luminal B).
    in high-risk patients, shorter EFSs were associated with low androgen subjects (HR 3.61) or high BRCAness characteristic expression (HR 3.58).
    BRCAness has been independently proven to be a predictor of EFS shortening (HR 2.64).
    about 13-15% of patients, rich in high-level, high-risk subsypes, with tumor inflammation characteristics (TIS) of high expression, suggesting that the anti-tumor immune response is inhibited.
    TIS score was associated with a strong number of TIL, but not with tumor mutation status.
    , BRCA-related DNA repair defects and tumor immunoreactive inhibition may be clinically relevant predictors of endocrine therapy, complementing treatment options for hormone-sensitive early breast cancer substations.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.